TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Want to see TMDX full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.6Last Year’s EPS
0.92Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicates solid top-line growth (21% YoY) and a strong cash position (~$462M), supported by clear, multi-year growth initiatives (CHOPS, OCS Kidney Gen 3.0, Gen 3.0 upgrades, and European NOP expansion) and reiterated full‑year guidance (20%–25% revenue growth). Near term, the company is absorbing deliberate, sizeable investments that compress gross and operating margins (gross margin down ~331 bps YoY; adjusted operating expenses up ~42% YoY), while donor-volume volatility and prior competitive-driven enrollment delays create execution and timing risk for clinical programs. Overall the call strikes a positive tone on growth and strategic direction but acknowledges tangible near-term margin and enrollment headwinds.Company Guidance
Strong Top-Line Growth
Total revenue of $174.0M in 1Q2026, up ~21% year-over-year and ~8% sequentially, demonstrating continued demand for the OCS platform and NOP services.
Robust U.S. and International Revenue Expansion
U.S. transplant revenue reported at approximately $167M (management breakdown) — ~20% YoY and ~8% sequential growth; international revenue was ~$5.6M, up ~39% YoY and ~17% sequentially, indicating accelerating international traction (albeit from a smaller base).
Product and Service Revenue Momentum
Total product revenue ~ $108M (up ~22% YoY, ~8% sequential) and service revenue ~ $66M (up ~19% YoY, ~9% sequential), with logistics/aviation utilization contributing meaningfully to service growth.
Profitability and Cash Position
Adjusted operating income of ~ $18M (adjusted operating margin ~10%); adjusted net income ~ $11M (EPS $0.30). Ended the quarter with ~$462M in cash and cash equivalents to fund investments and expansion.
Clear Multi-Front Growth Roadmap
Management reiterated full-year 2026 revenue guidance of $727M–$757M (20%–25% growth). Key strategic initiatives: ENHANCE and DENOVO clinical programs, CHOPS (controlled hypothermic system) with IDE supplement filing planned, OCS Kidney Gen 3.0 targeting early‑2027 IDE, Gen 3.0 upgrades for heart/lung/liver, and NOP Europe expansion including a PAD Aviation partnership.
Operational Logistics Strength
Maintained ~82% coverage of NOP missions requiring air transport and expects to maintain 22 operational aircraft in the U.S. fleet with plans to double-shift portions of the fleet to improve utilization and capacity.
TMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $94.93 | $72.92 | -23.19% |
Feb 27, 2026 | $145.26 | $147.00 | +1.20% |
Oct 29, 2025 | $134.32 | $135.79 | +1.09% |
Jul 30, 2025 | $107.70 | $118.97 | +10.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TransMedics Group Inc (TMDX) report earnings?
TransMedics Group Inc (TMDX) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is TransMedics Group Inc (TMDX) earnings time?
TransMedics Group Inc (TMDX) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMDX EPS forecast?
TMDX EPS forecast for the fiscal quarter 2026 (Q2) is 0.6.